Introduction
============

Numerous studies have shown that short-term exposure to particulate air pollution is associated with increased morbidity and mortality, primarily from cardiovascular disease (CVD) ([@b21]; [@b23]; [@b39]). The common and potentially toxic metal constituents of particulate matter (PM) air pollution have been associated with CVD in experimental and epidemiological studies ([@b13]; [@b26]; [@b38]; [@b40]). Foundry work has also been associated with CVD ([@b19]). In spite of the incorporation of state of-the-art methods to reduce noxious exposures in modern foundry facilities, workers are still exposed to high levels of airborne metal-rich PM ([@b43]).

The mechanisms by which PM exposure leads to CVD have not yet been fully elucidated. Inhaled fine PM may enter the circulatory system through the pulmonary capillary bed and promote atherothrombosis by breaching endothelial integrity, thereby inciting a local inflammatory reaction ([@b31]). However, whether fine particles physically enter and deposit in blood vessels is still contentious ([@b42]). There is evidence that a small fraction of fine and ultrafine particles accumulate in extrapulmonary organs, such as the liver and spleen ([@b29]). Alternatively, it has been proposed that ambient particles trigger pulmonary oxidative stress and inflammatory responses that lead to the release of proinflammatory signals into the circulatory system. Previous research has mainly focused on general inflammatory mediators and acute phase reactants, such as C-reactive protein, interleukin-6 and fibrinogen, rather than on mediators specifically induced by PM ([@b1]). Moreover, C-reactive protein and fibrinogen are not produced in the lungs and, therefore, do not represent a direct link between lung inflammatory responses and CVD.

Microvesicles (MVs) are circular fragments of the plasma membrane actively released from human cells. MV release may be induced by soluble agonists or in response to physical or chemical stress, such as oxidative stress ([@b36]). Growing evidence indicate that MVs represent a novel means for intercellular and between-tissue communication ([@b1]). MVs can travel from the tissue of origin to target cells, to which MVs transfer their contents by being internalized ([@b18]). MiRNAs are small, endogenous, single-stranded noncoding RNAs of 20-22 nucleotides ([@b30]) that regulate gene expression post-transcriptionally by either triggering mRNA cleavage or by repressing translation ([@b16]). Recent findings indicate that microRNAs (miRNAs) contained in MVs may determine reprogramming of gene expression in target cells and have therefore been indicated as potential determinants of intercellular and interorgan communication ([@b18]).

Bioinformatics models estimate that approximately one-third of the several thousand human genes may be regulated by miRNAs ([@b14]). A single miRNA can regulate hundreds of target mRNAs in interrelated genetic pathways, and a single mRNA can be targeted by several different miRNAs ([@b24]). MiRNA expression in circulating MVs has been detected in the plasma of healthy individuals, and growing evidence suggests that peripheral blood miRNA levels may play a role in predicting human diseases, such as cancer ([@b18]). In addition, alterations in the expression of several miRNAs have been found during oxidative stress ([@b2]) and inflammation ([@b44]). We recently showed modified expression of miRNAs involved in oxidative stress and inflammation in circulating blood leukocytes from electric-steel plant facility workers who were exposed to air particles rich in lead and cadmium ([@b5]). Other *in vitro* and *in vivo* studies have also shown effects on the expression of intracellular miRNAs from PM ([@b4]; [@b12]) or other exposures that include PM, such as diesel exhaust ([@b46]) or tobacco smoking ([@b10]; [@b27]).

Although the mechanisms linking air pollution and pulmonary inflammatory responses to vascular diseases are currently unknown, MVs are a plausible link because they can be produced by the respiratory system ([@b22]), can be disseminated through the circulatory system ([@b32]) and can lead to cardiovascular dysfunction ([@b34]). We investigated the hypothesis that PM and PM-associated metals could modify specific MV-associated miRNAs from plasma. To our knowledge, this is the first study to address this question. We measured the expression levels of 88 miRNAs contained within plasma MVs from 55 steel plant workers taken at the beginning of a working week (baseline) and after 3 days of work (postexposure). To evaluate a possible source of MV miRNAs, we also assessed the expression of miRNAs in MVs from A549 pulmonary cells treated with PM.

Methods
=======

*In Vivo* Study of Healthy Workers
----------------------------------

### Study participants

Sixty-three healthy male workers (mean age, 44 years; age range, 27--55 years) who had been employed for at least 1 year in a steel production plant near Brescia, northern Italy ([@b17]) were recruited for this study. Blood samples were obtained from 55 workers at two different times. The baseline sample was collected in the morning on the first day of a working week (after 2 days off from work) and before work activity began. The postexposure sample was collected at the same time on the fourth day of the working week after 3 consecutive days of work. Individual, written, informed consent from each participant and approval from the local Institutional Review Board ("Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico" review board) were obtained before the study.

### *Blood collection*, *microvesicle isolation and RNA extraction.*

Peripheral blood (7 ml) was collected in tubes containing EDTA, and the tubes were centrifuged at 400 *g* for 15 min to separate the plasma fraction from the blood cells. Aliquots of cell-free plasma were stored at -- 80 °C. Thawed samples were centrifuged three times at increasing speeds (1000 *g*, 2000 *g*, 3000 *g*) for 15 min at 4 °C to remove cell debris and aggregates. Supernatants were ultracentrifuged at 110 000 *g* for 2 h at 4 °C. Enriched miRNAs were isolated with the miRNeasy purification kit (Qiagen Hilden, Germany) following the manufacturer\'s instructions.

### MicroRNA profiling

RNA was converted to cDNA using universal reverse transcription (RT) primers (First Strand cDNA; Qiagen) and standard reverse transcription procedures. An eight-channel liquid handler (Microlab Starlet; Hamilton Robotics NV, USA) was used to increase throughput and reduce error. To analyze miRNA expression, we used miFinder RT^2^ miRNA polymerase chain reaction (PCR) arrays (SA Bioscience Quiagen Group, Hilden Germany) to measure the expression of 88 miRNA sequences (Table S1, Supplemental Materials). Real-time PCR was performed using RT^2^ qPCR MasterMix (Qiagen). Because there is no known control miRNA in MVs, small nucleolar (sno) RNAs were used as controls. The control primers used were SNORD48, SNORD47, SNORD44U38B and RNU6-2.

### Statistical analysis of healthy workers study

For miRNA expression levels, means and standard deviations were calculated for baseline and postexposure samples. The cycle threshold (*C*~t~) value was set to 40, and the relative quantification (*RQ*) was calculated using *RQ* = 2^-ΔCt^. Student\'s paired *t*-test was used to assess differences in miRNA expression between baseline and postexposure samples. MiRNAs that had expression differences of *P* \< 0.05 and a fold change \> 2.0 were considered differentially expressed miRNAs. An adjustment for multiple testing was performed using the Benjamini and Hochberg false discovery rate (FDR), which was set at \< 0.1 ([@b3]). Regression assumptions were checked to verify the normality and homogeneity of residual variances. To satisfy the normality assumptions of linear regression models, both miRNA expression and exposure values were log-transformed. All statistical analyses were performed with SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

### Enriched biological functions and network analysis

Predicted miRNA targets were identified using the miRNA target filter that connects miRNA data with experimentally observed and predicted mRNA targets using TargetScan and TarBase. Differentially expressed miRNAs and their targets were subjected to pathway exploration using the Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Redwood City, CA, USA).

In Vitro Study On A549 Pulmonary Cells
--------------------------------------

### Exposure of human A549 cells to particulate matter

The A549 human alveolar epithelial cell line (American Type Culture Collection, Manassas, VA, USA) was cultured in Dulbecco\'s modified Eagles medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (Invitrogen), 100 µg ml^--1^ penicillin and 100 U ml^--1^ streptomycin sulfate (Invitrogen) in a humidified incubator at 37 °C with 5% CO~2~. Nearly confluent cells were incubated for 24 h in the presence of PM. PM treatments were performed using SRM1648a (Standard Reference Material, National Institute of Standards and Technology) that was prepared from urban PM collected in St. Louis, MO, USA. The matter was removed from filter bags, combined into a single lot, screened to remove extraneous materials and thoroughly blended. Treatments were performed using 15, 31, 62, 125 or 250 µg ml^--1^ SRM1648a, and untreated cells were used as the control. Cells were harvested after 2, 6, 24 and 48 h of continuous exposure. Each treatment was performed in triplicate. The treatment concentrations of SRM1648a used did not affect cell viability.

### Cell viability and cell proliferation assays

A flow cytometry protocol (MACSQuant® Analyzer; Miltenyi Biotec Bergisch Gladbach, Germany) and propidium iodide dye were used to analyze cell viability. Cell proliferation was measured using the xCELLigence system (Roche Diagnostic, Basel, Switzerland) and E-Plate 96-well gold-coated plates (Roche Diagnostic). This system provides a real-time measurement of cell proliferation by measuring electrical impedance across microelectrodes integrated on the bottom of tissue culture E-Plates. The impedance measurement provides quantitative information about the biological status of the cells, including the cell number, viability and morphology. The more cells are attached to the electrodes, the greater the electrical impedance. The electrical impedance is converted to a dimensionless parameter termed cell index, which is a measure of the number of cells in a given well ([@b45]). Cells were plated at a concentration of 4000 cells per well on to an E-plate. After dilution in culture media, various concentrations of SRM1648a were added to wells, and the cell index was recorded at a frequency of 0.5 min^--1^.

### *Medium collection*, *microvesicle isolation and RNA extraction.*

Medium was collected from each plate and centrifuged three times at increasing speeds (1000 *g*, 2000 *g*, 3000 *g*) for 15 min at 4 °C to remove cell debris and aggregates. Supernatants were ultracentrifuged at 110 000 *g* for 75 min at 4 °C. Enriched miRNAs were isolated with the miRNeasy purification kit (Qiagen) following the manufacturer\'s instructions.

### Real time polymerase chain reaction

Differential expression of miRNAs was validated using TaqMan® MicroRNA Assays on an ABI Prism 7900HT system (Applied Biosystems, Uppsala, Sweden). For reverse transcription, 10 ng total RNA was used, and the incubation conditions were 16 °C for 30 min, 42 °C for 30 min, 85 °C for 5 min and 4 °C. Reagents were from the TaqMan MicroRNA RT kit (Applied Biosystems), and miRNA primers were from the TaqManR MicroRNA Assays kit. Real-time PCR was performed using TaqManR MicroRNA Assays together with the TaqManR Universal PCR Master Mix on an Applied Biosystems 7900 Sequence Detection System. The PCR cycling conditions were 95 °C for 1 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 30 s ([@b7]). Normalization was performed with the RNU6B endogenous control. Real-time PCR was performed in triplicate along with no-template controls. The *C*~t~ was defined as the fractional cycle number at which the fluorescence passes the fixed threshold. The *RQ* was calculated via the 2^−ΔΔCt^ method ([@b25]). Data were presented as relative quantities of target miRNA, normalized to the RNU6B endogenous control and a calibrator built by pooling all of the samples. All analyses were done simultaneously.

### Statistical analysis of in vitro data

A nonparametric test ([@b9]) was applied to investigate whether a dose-dependent trend occurred for each duration (2, 6, 24 or 48 h) of continuous PM exposure. This test is an extension of the Wilcoxon rank-sum test incorporating a correction for ties. Analyses were performed with SAS 9.2 (SAS Institute Inc.).

Results
=======

*In Vivo* Study of Healthy Workers
----------------------------------

### Characteristics of study participants

All 55 study participants were men, ranging from 27 to 55 years of age (mean, 44 years). Exposure levels for both the PM mass and metal varied widely among participants. The highest personal exposure level was 17 times greater than the lowest personal exposure level (i.e., for PM~10~, the maximum level was 1220.2 µg m^--3^ vs. the minimum level of 73.7 µg m^--3^). Additional details on the study group have been previously reported ([@b5]; [@b6]; [@b43]).

### Differential microRNA expression in plasma microvesicles of steel plant workers before and after particulate exposure

We compared the miRNA expression levels of the 55 baseline blood samples to those of the 55 paired postexposure blood samples. We identified six miRNAs that showed significant differential expressions (Table [1](#tbl1){ref-type="table"}). The most notable were miR-302c and miR-128 that were upregulated 13.95- and 5.62-fold, respectively (*P* \< 0.001). MiR-28-3p, let-7 g, miR-125a-5p and miR-181a were upregulated 3.64-fold (*P* = 0.01), 2.27-fold (*P* = 0.02), 2.98-fold (*P* = 0.04) and 1.72-fold (*P* = 0.02), respectively (Fig.[1](#fig01){ref-type="fig"}). When the FDR method was applied to account for multiple testing, both miR-302c and miR-128 passed the FDR threshold of \< 0.10, with FDRs of 0.06 and 0.05, respectively (Table [1](#tbl1){ref-type="table"}).

###### 

MicroRNAs with significant differential expression between baseline and postexposure samples

  MicroRNA          Mature sequence           Fold change   *P* value   False discovery rate
  ----------------- ------------------------- ------------- ----------- ----------------------
  hsa-miR-302c      UAAGUGCUUCCAUGUUUCAGUG    13.95         \< 0.001    0.06
  hsa-miR-128       UCACAGUGAACCGGUCUCUU      5.62          \< 0.001    0.05
  hsa-miR-28-3p     CACUAGAUUGUGAGCUCCUGG     3.64          0.01        0.30
  hsa-miR-125a-5p   UCCCUGAGACCCUUUAACCUGUG   2.98          0.04        0.54
  hsa-let-7 g       UGAGGUAGUAGUUUGUACAGU     2.27          0.02        0.37
  hsa-miR-181a      AACAUUCAACGCUGUCGGUGAG    1.72          0.02        0.37

![Volcano plot representing differential microRNA expression in plasma microvesicles of steel plant workers pre- and postexposure.](jat0035-0059-f1){#fig01}

### Predicted microRNA targets associated with diverse signaling networks

To characterize the functional relevance of the differentially expressed miRNAs and their potential interactions with different gene targets, we used the IPA® bioinformatics analysis approach. First, we identified putative downstream targets of the two differentially expressed miRNAs (miR-302c and miR-128) using the microRNA Target Filter, which connects miRNA data with experimentally observed and predicted mRNA targets and allows the selection of targets according to their biological relevance. Predicted relationships were derived from TargetScan, and experimentally observed relationships were derived from TarBase. Only predicted genes with high confidences were considered biologically relevant and acceptable for IPA analysis. A total of 919 mRNA targets were predicted for miR-302c, whereas 894 mRNA targets were predicted for miR-128.

We evaluated the relationships of miR-302c and miR-128 with their respective target genes by analyzing their networks. A network consisted of the direct and indirect interactions between the uploaded predicted targets and other interacting molecules in the Ingenuity Knowledge Base. These interactions were grouped such that there were a maximum of 35 molecules per network. Ingenuity analysis on miR-302c identified two primary networks, with functions related to (1) dermatologic disease and conditions, infectious disease and developmental disorder (31 of 35, score 43), and (b) cell morphology, cellular function and maintenance and connective tissue development and function (31 of 35, score 43). Ingenuity analysis on miR-128 identified two primary networks, with functions related to (1) connective tissue development and function, connective tissue disorders and developmental disorder (31 of 35, score 44), and (2) organ development, respiratory system development and function, and skeletal and muscular system development and function (31 of 35, score 44). Table [2](#tbl2){ref-type="table"} identifies the top five networks, functions and molecules associated with the miR-302c and miR-128 targets.

###### 

Top five networks, functions and molecules associated with miR-302c and miR-128 targets identified by Ingenuity Pathway Analysis software analysis

  Network   Top functions                                                                                                           Score          Focus molecules   Molecules in network
  --------- ----------------------------------------------------------------------------------------------------------------------- -------------- ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                    hsa-miR-128                      
  1         Connective tissue development and function, connective tissue disorders, developmental disorder                         44             31                BCR, C11orf41, C17orf70, CLIC4, CSDC2, CYP4F2, DAZAP2, DLGAP3, FANCA, Fgf, FUBP3, GNS, GRB2, LASP1, LPCAT1, MAP2K1/2, NAP1L5, NEDD4, NKX3-2, PAX9, PIK3R1, ProSAPiP1, RBM33, REPS1, Sapk, SCAMP3, SHANK3, SMAD5, SMAP1, SMURF2, SOX7, SPRY2, SPTBN1, WIPF2, ZNF24
  2         Organ development, respiratory system development and function, skeletal and muscular system development and function   44             31                AFF4, AK2, C5orf13, C7orf42, CDC14B, CTDSP2, CTDSPL, EYA4, FAM177A1, FOXP2, FOXP4, FRYL, GNG12, Ige, INO80D, MAN2A1, MAPK14, MED13, MED14, Mediator, Mek, MET, MIR124 (human), NAA15, NAA50, NIPBL, PDPN, PTPN3, RAI14, RUVBL2, SASH1, SNAI1, TLK2, YWHAB, ZCCHC24
  3         Post-translational modification, protein degradation, protein synthesis                                                 39             29                ANK1, ARRDC4, DTX1, DTX3L, E2F7, EDAR, GFPT2, Ikk (family), ITCH, KLF3, LIN28A, Mapk kinase, MARCH5, MFHAS1, MIR125B (human), N4BP1, NF-κB (complex), NFX1, PELI3, PPARα-RXRα, RNF182, RNF144A, SNX18, TAB3, TBC1D1, TMOD2, TRIM23, TRIM32, TXNIP, UBA6, UBE2, UBE2E2, UBE2N, UBE2V1, WTAP
  4         Connective tissue disorders, developmental disorder, skeletal and muscular disorders                                    39             29                ATXN10, CCDC71, CCM2, CNOT6, FADS1, FBLN2, Gsk3, H3F3A/H3F3B, HAND2, HCN4, HDAC4, HDAC5, HIC1, Histone h3, Histone h4, HOXA10, HOXA13, HOXB3, ING5, IRF4, MEIS2, MIR1, MMD, MYST2, NAV2, NFAT (complex), Notch, NOVA1, PCM1, PHF15, PHGDH, POM121/POM121C, RERE, SIRT1, SLC7A11
  5         Gene expression, cardiac output, cardiovascular system development and function                                         38             29                26 s Proteasome, ARHGAP21, Caspase, CPD, Cytochrome c, DUSP5, FSH, GCC2, GIGYF2, INSR, KIAA1033, KIAA1109, KITLG, MEPCE, MN1, MNT, NCAM1, NEK1, NRP2, OPA1, PDHX, PLXND1, POGZ, PP2A, PRDM16, RUNX1, SERTAD2, SMAD2, SP1, SP4, SRP72, TNRC6B, UBE2NL, Vegf, ZNHIT6
                                                                                                                                    hsa-miR-302c                     
  1         Dermatological diseases and conditions, infectious disease, developmental disorder                                      43             31                Ahr-aryl hydrocarbon-Arnt, ALDH1B1, BCL11A, BCL11B, CC2D1A, E2F7, EDAR, GABPB1, Ikk (family), IL1F9, IRAK4, KLF3, LMO3, MICA, NCOA7, NF-κB (complex), NHLH2, NR2F2, PELI1, RNF216, RORA, TAX1BP1, TPMT, TRAFD1, TRIM8, TRIM36, TRIP11, UBE2, UBE2B, UBE2G1, UBE2H, UBE2J1, UBE2R2, UBE2V1, ZFPM2
  2         Cell morphology, cellular function and maintenance, connective tissue development and function                          43             31                ADD3, ANK2, BRCC3, CRTC2, DCAF7, DCTN4, DUSP2, Dynein, DYRK2, ERK1/2, FAM175B, KIF3B, KLF13, MARCH5, MARK1, MARK3, MFN2, MIB1, MTUS1, Na+,K + -ATPase, NEFL, NTN4, Rab5, RAB5C, RABEP1, RAPGEF2, RB1CC1, SCN2A, SHC4, SIK1, TRIM2, UBE2W, ULK1, WDR26, WDR76
  3         Digestive system development and function, gene expression, embryonic development                                       37             28                ACVR1C, ALX4, ARL4D, BAMBI, CCDC25, CDC40, DAZAP2, DCUN1D1, FOXP1, GATAD2B, Groucho, LEF1, Lefty, LEFTY1, LEFTY2, Mapk, MNT, MXD1, NFYA, PALLD, PRDM16, PRRX1, PURB, RGMA, RUNX3, Smad, SMAD2, Smad1/5/8, Smad2/3, TGFBR, TGFBR2, TLE4, TNRC6B, TPD52L1, TPD52L3
  4         Cell cycle, gene expression, molecular transport                                                                        35             27                20s proteasome, 26 s Proteasome, BNIP3L, CCND1, CDCA7, CUL3, DIP2B, DMTF1, FAM40B, FOXO3, HMGCS2, Ikb, IKK (complex), IRF, MAP3K14, MHC CLASS I (family), NCOA3, NfkB1-RelA, ORC4, POC5, POLK, POLQ, RAD18, RAD23B, SIKE1, SLC40A1, SPOP, SQSTM1, STEAP3, TAPT1, TP53INP2, UBE3A, Ubiquitin, XIAP, ZRANB1
  5         Tissue morphology, behavior, nervous system development and function                                                    33             28                ABCG2, APP, ATF6B, BCL2L11, CALML4, COL11A1, cytochrome *c*, cytochrome *c* oxidase, DKK1, DNAJA2, DNAJC10, DNAJC21, FMR1, HNRNPF, HNRNPUL2, Hsp27, Hsp70, Hsp90, Hsp22/Hsp40/Hsp90, ICK, IGF2BP1, KBTBD8, KREMEN1, MYT1L, NAALADL2, NFYB, NUFIP2, PTPRD, RNA polymerase II, RTN1, STX16, TARDBP, TP63, TSNAX, ZFPM1

To test for cross-talk between networks targeted by the differentially expressed miRNAs, we used the IPA algorithm for overlaying and merging networks. Network analysis of the top molecular and cellular functions showed that, of the 25 networks identified as significant by the software, all were predicted to play roles in cross-talk with peripheral molecules bridging different networks (supplementary Fig. S1). NF-κB was found to be a central molecule in the networks of both miR-302c and miR-128 (Supplementary Fig. S2).

### Mapping differentially expressed microRNAs and their target genes to Tox Lists

Tox Lists are lists of molecules that are known to be involved in a particular type of toxicity. The IPA software maps differentially expressed genes to Tox Lists to uncover pathways altered by toxicant exposure. The two differentially expressed miRNAs and their respective target genes were mapped to these lists, and altered pathways (*P* \< 0.05) were identified. MiR-302c targets mapped to five Tox List pathways (increases cardiac dysfunction, G~1~/S checkpoint regulation, hypoxia-inducible factor signaling, p53 signaling and cardiac hypertrophy), whereas miR-128 targets mapped to six altered pathways (hormone receptor regulated cholesterol metabolism, liver proliferation, transforming growth factor-β signaling, retinoic acid receptor activation, peroxisome proliferator activated receptor-α/retinoid X receptor-α activation and mechanism of gene regulation by peroxisome proliferators via peroxisome proliferator activated receptor-α).

*In Vitro* Study on A549 Pulmonary Cells
----------------------------------------

### Effects of particulate matter treatment on proliferation of A549 cells

We examined the effect of increasing PM doses on the proliferation of A549 cells with the xCELLigence detection system (Roche Diagnostic, Basel, Switzerland) and found a significant dose-dependent decrease in cell proliferation over time. Each PM concentration was tested 12 times. The average (means ± SD) doubling times were 22.5 ± 1.7, 17.4 ± 1.3, 17.4 ± 0.9, 16.6 ± 0.8, 15.8 ± 1.1 and 16.3 ± 0.8 h for cells treated with 250, 125, 62, 31, 15 and 0 µg ml^--1^ PM, respectively (Fig.[2](#fig02){ref-type="fig"}).

![Growth profile of A549 cells treated with increasing doses of PM~10~.](jat0035-0059-f2){#fig02}

### Expression of miR-128 and miR-302c in microvesicles from A549 cells treated with particulate matter

We determined by quantitative RT-PCR the expression levels of miR-302c and miR-128 in MVs purified from culture media of PM-treated A549 cells. MiR-128 was significantly upregulated in MVs from treated cells (Fig.[3](#fig03){ref-type="fig"}). The upregulation was dose-dependent after 6 h (*P* = 0.030), 24 h (*P* = 0.025) and 48 h (*P* = 0.010) of treatment. No dose dependence was observed at the earliest time point (2 h of treatment; *P* = 0.338). MiR-302c was undetectable in MVs from the culture media of either PM-treated or untreated cells. MiR-302c was not detectable in A549 cells or in lung reference RNA (First Choice Human Lung Total RNA; Ambion, Life Technologies, CA, USA) (data not shown).

![miR-128 expression in microvesicles purified from culture media of A549 cells treated with increasing doses of PM~10~ at different times.](jat0035-0059-f3){#fig03}

Discussion
==========

In this study, we evaluated the expression of 88 MV-associated microRNAs, isolated from the plasma of healthy, electric steel plant facility workers, in response to PM exposure. We identified two miRNAs, miR-128 and miR-302c, that may be involved in the molecular response to air pollution. To provide information about the potential tissue of origin of the miRNAs found in plasma MVs, we evaluated expression of these two miRNAs *in vitro* in MVs released from A549 pulmonary cells treated with PM. The *in vitro* experiment showed that PM induced the expression of miR-128 in A549, but not of miR-302c, which was not expressed in MVs from A549 cells, in RNA extracted from A549 cells, or in reference RNA from lung tissue. Taken together, these results are consistent with the hypothesis, summarized in Fig.[4](#fig04){ref-type="fig"}, that PM exposure induces the release of specific miRNAs (e.g., miR-128) in MVs generated from alveolar or other lung cells and that such MV-contained miRNAs can be detected in plasma. In turn, MV-contained miRNAs could travel to tissues critical to the PM cardiovascular events, such as blood and tissue leukocytes, endothelial cells and other cardiovascular tissues to reprogram their gene expression and contribute to determine PM-induced outcomes, such as inflammation, blood clotting or atherosclerosis. While our results indicate that PM induces release in plasma of miRNAs originating from lung tissues, further research is needed to determine whether they participate in the pathways leading to adverse health effects.

![Possible roles of plasma microvesicle microRNAs in mediating cardiovascular effects of particular matter.](jat0035-0059-f4){#fig04}

Epidemiological studies have linked short-term exposure to PM in urban environments with increased morbidity and mortality from CVD ([@b21]; [@b23]; [@b39]). The acute effect of PM on the cardiovascular system has been linked to a time window of exposure as short as 1--5 days before adverse events. More protracted exposure has also been linked with atherosclerosis and long-term cardiovascular risk. Although many studies have compared miRNA expression in target tissue between diseased and healthy samples, very few studies have evaluated changes in miRNA expression in response to environmental stimuli ([@b5]; [@b8]; [@b11]; [@b15]; [@b20]; [@b35]). In the present study, blood samples were collected from PM-exposed workers on the first and last days of the same working week, and the samples showed an increase in miR-128 and miR-302c expression. These changes over a short period of exposure indicate that miR-128 and miR-302c may be part of rapid, molecular changes caused by PM exposure. To our knowledge, this is the first study suggesting that PM exposure alters expression of MV-associated miRNAs, thus indicating a novel mechanism of air pollution toxicity.

To investigate further whether PM stimulates expression of MV-contained miR-128 and miR-302c in a possible cell type of origin of the plasma MVs, we treated A549 human alveolar epithelial cells with increasing doses of PM. Using this *in vitro* model, we confirmed the upregulation of MV-contained miR-128 upon exposure to PM. The increase in miR-128 expression was dose-dependent, and the maximum effect was reached after 48 h of continuous treatment. Cell growth was slowed, but cell viability was not affected by the PM concentrations tested. Our data, plus previous data showing that PM inhalation increased interferon production in the lung ([@b41]) and that interferon rapidly modulated the *in vitro* expression of several cellular miRNAs, including miR-128 ([@b33]; [@b37]), together suggest that mir-128 may play a role in the molecular response to PM.

The differential expression of miR-128 could arise from two different mechanisms. It is possible that each MV released from PM-treated cells contains higher concentrations of miR-128, or that PM-treated cells release a larger number of MVs containing miR-128. Because we used an endogenous small RNA contained in MV instead of an external synthetic RNA to normalize our expression data, we may have effectively measured an increase in the number of miRNA copies carried by each MV. Nevertheless, it is not possible to exclude the possibility that the number of MVs increased, thereby increasing the number of miRNA molecules.

Contrary to what we observed for miR-128, we were unable to detect miR-302c in MVs from culture media of either PM-treated or untreated A549 cells. To understand this result, we also measured the amount of miR-302c in RNA from untreated A549 cells and in lung reference RNA, and we found no detectable miR-302c. This finding demonstrated that miR302c is not expressed in these pulmonary cells. Taken together, these results may indicate that the increased expression of miR-302c found in the plasma of workers exposed to PM may have been due to MVs produced in other cell types of tissues. For instance, they may have been produced by alveolar macrophages exposed to PM in the pulmonary environment. Alternatively, because a large proportion of circulating MVs are released from blood cells ([@b18]), the increased miR-302c expression might have originated from circulating cells known to respond to PM exposure, such as leukocytes or platelets.

The limitations of our *in vivo* experiments were the inability to characterize the origin(s) of the MVs and the limited number of miRNAs evaluated. Although flow cytometry can be used to separate circulating MVs based on their tissue sources, this approach can only be done in fresh plasma. In our study, blood samples were collected, processed and frozen in the foundry; thus, we were unable to perform tissue-specific separation of MVs. Secondly, due to the limited amount of plasma available, we extracted only a small quantity of miRNAs, which was sufficient to perform real-time PCR on only 88 miRNAs for each subject. We chose this approach because of the higher precision and sensitivity of real-time PCR compared to microarray technology. Real-time PCR is considered the gold standard for gene expression analysis and is commonly used to validate microarray data ([@b28]). Currently available microarrays are also not specific enough to differentiate expression of closely related miRNAs that differ in sequence by only one base. Moreover, real-time PCR analysis reduced the number of statistical comparisons, which provided higher statistical power to detect moderate effects. An advantage of this study was the use of an occupational group exposed to a well-characterized PM. The relatively controlled environment of the foundry and the relative homogeneity of the study participants reduced bias and chance findings, and provided an optimal setting for the evaluation of mechanistic questions.

Because research on MV-associated miRNAs is limited, no housekeeping gene has been validated for the normalization of MV-associated miRNA expression data. As our controls, we used the housekeeping genes SNORD48, SNORD47, SNORD44 and RNU6-2 that have been widely used to normalize miRNAs in different tissues. Using statistical methods, we evaluated the variability of the housekeeping genes among our samples. To reduce bias, we normalized our data using the average of the four controls.

A large proportion of plasma MVs from normal subjects are derived from blood cells ([@b18]). However, plasma miRNAs and MVs may be released upon damage from local tissues and delivered remotely to target cells for specific functions ([@b18]). The discovery of miRNAs in plasma MVs of healthy subjects ([@b18]) provides the basis for a putative, novel mechanism that may explain the cardiovascular effects of PM exposure. In this mechanism, MVs produced by lung or dendritic cells can transfer a specific selection of miRNAs to cells of the immune system and to endothelial cells. IPA analysis of the differentially expressed miRNA-128 and miRNA-302c demonstrated that these miRNAs potentially affect genes that play a central role in air pollution-linked pathologies, such as CVD. Moreover, our *in silico* analyses suggested links between miR-128 and coronary artery disease and between miR-302c and coronary artery disease, cardiac hypertrophy and heart failure. However, these hypotheses need to be investigated in a population showing specific CVD symptoms.

Conclusion
==========

In summary, this study provides evidence from a human *in vivo* investigation reinforced by an *in vitro* experiment that expression of extracellular miRNAs contained in MVs is rapidly altered upon exposure to an environmental pollutant. We identified two miRNAs, miR-128 and miR-302c, that are potentially involved in the molecular responses to PM air pollution exposure. The dose--response relationship found in MVs from PM-treated A549 cells for miR-128 suggests that the miR-128 response might originate from pulmonary alveolar cells. Our findings might have relevant clinical and public health implications. Plasma is a biological medium that is easily obtained from both patients and exposed healthy individuals. Findings on plasma MVs have the potential for translation to future preventive and diagnostic applications. Further, MV-associated miRNAs may be eventually used as therapeutic drug targets and pave the way for interventions to reverse some of the detrimental effects of air pollution. Despite some limitations, our findings are the first to demonstrate that air particles, particularly those rich in metals, alter expression of MV-associated miRNAs. Further studies to elucidate the origins of MVs and to profile miRNAs in a larger population are required.
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